Mostrar el registro sencillo del ítem

dc.contributor.authorPagliari, M.T.
dc.contributor.authorRosendaal, F.R.
dc.contributor.authorAhmadinejad, M.
dc.contributor.authorBadiee, Z.
dc.contributor.authorBaghaipour, M.-R.
dc.contributor.authorBaronciani, L.
dc.contributor.authorBenítez Hidalgo, O.
dc.contributor.authorBodó, I.
dc.contributor.authorBudde, U.
dc.contributor.authorCastaman, G.
dc.contributor.authorEshghi, P.
dc.contributor.authorGoudemand, J.
dc.contributor.authorKarimi, M.
dc.contributor.authorKeikhaei, B.
dc.contributor.authorLassila, R.
dc.contributor.authorLeebeek, F.W.G.
dc.contributor.authorLópez Fernández, María Fernanda 
dc.contributor.authorMannucci, P.M.
dc.contributor.authorMarino, R.
dc.contributor.authorOldenburg, J.
dc.contributor.authorPeake, I.
dc.contributor.authorSantoro, C.
dc.contributor.authorSchneppenheim, R.
dc.contributor.authorTiede, A.
dc.contributor.authorToogeh, G.
dc.contributor.authorTosetto, A.
dc.contributor.authorTrossaert, M.
dc.contributor.authorYadegari, H.
dc.contributor.authorZetterberg, E.M.K.
dc.contributor.authorPeyvandi, F.
dc.contributor.authorFederici, A.B.
dc.contributor.authorEikenboom, J.
dc.date.accessioned2025-08-26T09:29:06Z
dc.date.available2025-08-26T09:29:06Z
dc.date.issued2022
dc.identifier.citationPagliari MT, Rosendaal FR, Ahmadinejad M, Badiee Z, Baghaipour M-R, Baronciani L, et al. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study. Journal of Thrombosis and Haemostasis. 2022;20(5):1106-14.
dc.identifier.issn1538-7836
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/63389a28250f6f21353612e0*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20680
dc.description.abstractBackground: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWF:Ag) and factor (F)VIII coagulant activity (FVIII:C) over VWF:Ag. Objective: To investigate whether the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity. Methods: European and Iranian type 3 patients were enrolled in the 3WINTERS-IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWF:Ag, VWFpp, FVIII:C, and genetic analyses were performed centrally, to confirm patients' diagnoses. VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were compared among different variant classes using the Mann-Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges-Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman's rank correlation. Results: Homozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWF:Ag ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2-2.7; P =.016]; [VWFpp/VWF:Ag median difference, 1.4; 95% CI, 0-4.2; P =.054]). FVIII:C/VWF:Ag ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r =.024; P =.778). Conclusions: An increased VWFpp/VWF:Ag ratio is indicative of missense variants, whereas FVIII:C/VWF:Ag ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype.en
dc.description.sponsorshipWe would like to thank the Members and current Chair of the Sub-Committee on VWF of the Scientific Standardization Committee (SSC) of the ISTH who promoted the endorsement of 3WINTERS-IPS project among the scientific activities of this Sub-Committee. We also would like to thank Javier Battle, Erik Berntorp, Cosimo Ettore, Charles R. M. Hay, Hamid Hoorfar, Maria Gabriella Mazzucconi, Massimo Morfini, Rafael Parra Lopez, and Omidreza Zekavat for patient enrolment and collections of clinical data and Anne Goodeve for her work on genotyping. The 3WINTERS-IPS project received unconditional research grants from several pharmaceutical companies and therefore we acknowledge the representatives of Baxter-Shire-Takeda, Grifols, CSL Behring, LFB, and Octapharma. This work was partially supported by the Hungarian National Research Development and Innovation Office (NFKI) grant OTKA-K19_131945 (I.B.). This work was partially supported by the Italian Ministry of Health-Bando Ricerca Corrente (F.P.). We wish to thank Paolo De Simoni, Luca Maravigna, and Elisabetta Musazzi of the CRO Sintesi Research for the study coordination. We acknowledge L. F. Ghilardini for the illustration work.en
dc.language.isoeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleVon Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study*
dc.typeArticleen
dc.authorsophosPagliari, J. M. T.
dc.authorsophosRosendaal, F. R.
dc.authorsophosAhmadinejad, M.
dc.authorsophosBadiee, Z.
dc.authorsophosBaghaipour, M. R.
dc.authorsophosBaronciani, L.
dc.authorsophosBenítez Hidalgo, O.
dc.authorsophosBodó, I.
dc.authorsophosBudde, U.
dc.authorsophosCastaman, G.
dc.authorsophosEshghi, P.
dc.authorsophosGoudemand, J.
dc.authorsophosKarimi, M.
dc.authorsophosKeikhaei, B.
dc.authorsophosLassila, R.
dc.authorsophosLeebeek, F. W. G.
dc.authorsophosLopez Fernandez, M. F.
dc.authorsophosMannucci, P. M.
dc.authorsophosMarino, R.
dc.authorsophosOldenburg, J.
dc.authorsophosPeake, I.
dc.authorsophosSantoro, C.
dc.authorsophosSchneppenheim, R.
dc.authorsophosTiede, A.
dc.authorsophosToogeh, G.
dc.authorsophosTosetto, A.
dc.authorsophosTrossaert, M.
dc.authorsophosYadegari, H.
dc.authorsophosZetterberg, E. M. K.
dc.authorsophosPeyvandi, F.
dc.authorsophosFederici, A. B.
dc.authorsophosEikenboom
dc.identifier.doi10.1111/jth.15658
dc.identifier.sophos63389a28250f6f21353612e0
dc.issue.number5
dc.journal.titleJournal of Thrombosis and Haemostasis*
dc.page.initial1106
dc.page.final1114
dc.relation.projectIDBaxter-Shire-Takeda; Grifols; CSL Behring; LFB; Octapharma; Hungarian National Research Development and Innovation Office (NFKI) [OTKA-K19_131945]; Italian Ministry of Health-Bando Ricerca Corrente
dc.relation.publisherversionhttps://www.jthjournal.org/article/S1538783622001544/pdf;https://www.jthjournal.org/article/S1538-7836(22)00154-4/pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Coruñaes
dc.subject.keywordCHUACes
dc.subject.keywordINIBICes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number20


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International